Announcements Trials

Browse Landscape

Phase

Phase NA 39 Phase 3 7 Phase 2 6 Phase 1 3 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Genitourinary 1 Gastrointestinal 1

Conditions

Prostatic Neoplasms 76 Urinary Bladder Neoplasms 20 Neoplasms 11 Carcinoma, Transitional Cell 8 Non-Muscle Invasive Bladder Neoplasms 6 Lung Neoplasms 6 Carcinoma, Renal Cell 6 Neoplasm Metastasis 5 Breast Neoplasms 4 Testicular Neoplasms 3 Recurrence 3 Prostatic Neoplasms, Castration-Resistant 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Kidney Neoplasms 3 Colorectal Neoplasms 3 Carcinoma in Situ 3 Adenocarcinoma 3 Acute Kidney Injury 3 Uterine Cervical Neoplasms 2 Prostate CA 2 Melanoma 2 Liver Neoplasms 2 Kidney Failure, Chronic 2 Hematologic Neoplasms 2 Head and Neck Neoplasms 2 Gallbladder Neoplasms 2 Critical Illness 2 Colonic Neoplasms 2 Agnosia 2

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Disease × Genitourinary × Clear all

NCT02981368 2021-08-09

OSPREY

Progenics Pharmaceuticals, Inc.

Phase 2/3 Completed

385 enrolled 20 charts

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡